Larimar Therapeutics is a biotechnology company, developing a treatment for Friedreich’s ataxia (FA) called CTI-1601. CTI-1601 replaces frataxin, which is the protein that is reduced in FA.
Larimar Therapeutics recently announced that the first cohort for their Phase 2 trial has enrolled all participants, and is proceeding as planned. This 4 week trial is designed to identify the best dose of CTI-1601. They expect to provide an update on this trial later this year, when their data has been reviewed by the US regulators (the FDA).
This Phase 2 trial is taking place in the US.
For more information, read the full press release.
